Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.
- FDA endorses Phase 3 study population and dosing
- Primary endpoint set as UMSARS Part I with 48% progression slowing
- Phase 3 trial initiation planned for year-end 2026
- ATH434 holds Fast Track and Orphan Drug designations
- Phase 2 data demonstrated clinically significant efficacy
FDA Agreement Clears Path for ATH434 Phase 3 Trial
Alterity Therapeutics (ASX:ATH) has achieved a crucial regulatory milestone with the U.S. Food and Drug Administration endorsing the design of its pivotal Phase 3 clinical trial for ATH434 in Multiple System Atrophy (MSA). The FDA’s alignment on the study population, dosing regimen, treatment duration, and primary endpoint significantly de-risks the development program and sets a clear path toward potential regulatory approval.
The Phase 3 trial will use the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I as its primary endpoint, a functional rating scale measuring disease progression. This follows Phase 2 results where ATH434 demonstrated a 48% slowing of disease progression compared to placebo, a clinically and statistically significant outcome that underpins the trial design. The FDA also agreed on the 50 mg twice daily dosing, the dose level that delivered the positive Phase 2 efficacy signals.
Trial Design and Secondary Endpoints
The upcoming Phase 3 study will randomize approximately 200 patients with clinical and biomarker evidence of MSA to receive either ATH434 or placebo over 12 months. The FDA has also endorsed key secondary endpoints, including the Swallowing Disturbance Questionnaire, Orthostatic Hypotension Symptom Assessment, and Clinical Global Impression of Severity, which together aim to provide a comprehensive assessment of efficacy.
Statistical methods proposed for analyzing both primary and secondary endpoints have received FDA concurrence, and the agency considers the anticipated safety database from the trial to be sufficient. This regulatory clarity is a significant step forward for Alterity as it prepares to finalise the Phase 3 protocol and initiate trial activities by the end of 2026.
Building on Strong Phase 2 Foundations
ATH434’s Phase 2 trial, a randomized, double-blind, placebo-controlled study involving 77 patients, showed robust clinical efficacy and target engagement, alongside a favourable safety profile. The trial employed neuroimaging, protein biomarkers, and wearable sensors to capture multiple dimensions of disease impact, with results reinforcing ATH434’s potential as a disease-modifying therapy for MSA.
The drug’s mechanism involves redistributing excess iron and inhibiting abnormal protein aggregation linked to neurodegeneration, addressing a key pathological hallmark of MSA. ATH434 has already earned Fast Track and Orphan Drug designations from the FDA, recognising the urgent unmet need in this rare and rapidly progressing disease.
Implications for Patients and Investors
Multiple System Atrophy remains a devastating condition with no approved therapies to slow its progression. Alterity’s progress with ATH434 offers a rare glimmer of hope for patients facing profound disability. From an investor perspective, the FDA’s endorsement reduces regulatory uncertainty and strengthens confidence in the company’s clinical strategy and timeline.
CEO David Stamler highlighted the significance of the FDA alignment as an important de-risking milestone, underscoring the company’s readiness to advance into the final stage of clinical development. The upcoming Phase 3 trial will be closely watched as the definitive test of ATH434’s potential to alter the course of MSA.
Bottom Line?
FDA’s endorsement of ATH434’s Phase 3 design sharpens Alterity’s clinical and regulatory focus as it targets trial start by year-end 2026.
Questions in the middle?
- Will the Phase 3 trial replicate the 48% slowing of disease progression seen in Phase 2?
- How will recruitment and retention of MSA patients progress given the disease’s rarity and rapid progression?
- What interim data or regulatory interactions might provide early signals ahead of trial completion?